Sucha Nand
  • Professor
  • Hematology/Oncology
Blood Disorders, Leukemia, Cancers of the Blood and Blood Cells, Bone Marrow Disorders, Non-Hodgkin's Lymphoma, Clotting Disorder, Diagnosis of Bleeding or Clotting Disorders, Multiple Myeloma, Hodgkin's Lymphoma
Board Certifications
  • Hematology - Subspecialty Cert: AM Board of Internal Medicine
  • Internal Medicine - General Cert: AM Board of Internal Medicine
  • Medical Oncology - Subspecialty Cert: AM Board of Internal Medicine

FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL CellsYou,D.; Xin,J.; Volk,A.; Wei,W.; Schmidt,R.; Scurti,G.; Nand,S.; Breuer,E. K.; Kuo,P. C.; Breslin,P.; Kini,A. R.; Nishimura,M. I.; Zeleznik-Le,N. J.; Zhang,J.Cell reports 2015 ;10(12):2055-2068

Anemias excluding cobalamin and folate deficienciesDublis,S.; Shah,S.; Nand,S.; Anderes,E.Handbook of clinical neurology 2014 ;120( ):1005-1014

Anaplastic large cell lymphoma involving the urinary bladder: A case report and review of the literatureChen,H.; Li,Y.; Nand,S.; Quek,M. L.; Kini,A. R.; Barkan,G. A.Diagnostic cytopathology 2014 ; ( ):

Commonly used drugs in hematologic disordersAnderes,E.; Nand,S.Handbook of clinical neurology 2014 ;120( ):1125-1139

Heckathorn disease revisitedNand,S.; Barton,K.; Schultz,R.; Klein,M.; Kini,A.Blood 2014 ;123(9):1429-1431

A phase II trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaNand,S.; Othus,M.; Godwin,J. E.; Willman,C. L.; Norwood,T. H.; Howard,D. S.; Coutre,S. E.; Erba,H. P.; Appelbaum,F. R.Blood 2013 ; ( ):

Cerebral Vein and Dural Venous Sinus Thrombosis: Risk Factors, Prognosis and Treatment—a Modern ApproachPaner,A.; Jay,W. M.; Nand,S.; Michaelis,L. C.Neuro-Ophthalmology 2009 ;33(5):237-247

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trialNand,S.; Godwin,J.; Smith,S.; Barton,K.; Michaelis,L.; Alkan,S.; Veerappan,R.; Rychlik,K.; Germano,E.; Stiff,P.Leukemia & lymphoma 2008 ;49(11):2141-2147

Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorderPortell,C.; Nand,S.Blood 2008 ;111(8):4416-4417

Inherited thrombophilia and the eyeCzerlanis,C.; Jay,W. M.; Nand,S.Seminars in ophthalmology 2008 ;23(2):111-119

Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challengeNand,S.; Barton,K.Leukemia & lymphoma 2007 ;48(2):215-216

A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy.Naeem,M.; Harrison,K.; Barton,K.; Nand,S.; Alkan,S.European journal of haematology 2006 ;76(2):164-166

Thromboembolism in cancer patients: pathogenesis and treatmentAdess,M.; Eisner,R.; Nand,S.; Godwin,J.; Messmore,H. L.,Jr; Wehrmacher,W. H.Clinical & Applied Thrombosis/Hemostasis 2006 ;12(3):254-266

Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition.Alkan,S.; Huang,Q.; Ergin,M.; Denning,M. F.; Nand,S.; Maududi,T.; Paner,G. P.; Ozpuyan,F.; Izban,K. F.American Journal of Hematology 2005 ;79(2):97-106

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.Houde,C.; Li,Y.; Song,L.; Barton,K.; Zhang,Q.; Godwin,J.; Nand,S.; Toor,A.; Alkan,S.; Smadja,N. V.; Avet-Loiseau,H.; Lima,C. S.; Miele,L.; Coignet,L. J.Blood 2004 ;104(12):3697-3704

Lymphoproliferative disorders in chronic hepatitis C.Idilman,R.; Colantoni,A.; De Maria,N.; Alkan,S.; Nand,S.; Van Thiel,D. H.Journal of viral hepatitis 2004 ;11(4):302-309

Herpes zoster during treatment with arsenic trioxideTanvetyanon,T.; Nand,S.Annals of Hematology 2004 ;83(3):198-200

Pancytopenia in hereditary haemorrhagic telangiectasia.Tanvetyanon,T.; Nand,S.British journal of haematology 2004 ;127(4):371

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesHesketh,P. J.; Arena,F.; Patel,D.; Austin,M.; D'Avirro,P.; Rossi,G.; Colowick,A.; Schwartzberg,L.; Bertoli,L. F.; Cole,J. T.; Demetri,G.; Dessypris,E.; Dobbs,T.; Eisenberg,P.; Fleischman,R.; Hall,J.; Hoffman,P. C.; Laber,D. A.; Leonard,J.; Lester,E. P.; McCachren,S.; McMeekin,S.; Meza,L.; Miller,D. S.; Nand,S.; Oliff,I.; Paroly,W.; Pawl,L.; Perez,A.; Raftopoulos,H.; Rigas,J.; Rowland,K.; Scullin,D. C.,Jr; Tezcan,H.; Waples,J.; Ward,J.; Yee,L. K.Cancer 2004 ;100(4):859-868

Hairy cell leukemia variant developing in a background of polycythemia veraKelly,N. P.; Alkan,S.; Nand,S.Archives of Pathology & Laboratory Medicine 2003 ;127(4):e209-11

Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing.Tanvetyanon,T.; Nand,S.Annals of Pharmacotherapy 2003 ;37(12):1818-1820

Hepatitis C virus infection and lymphoproliferative disordersPena,L. R.; Nand,S.; De Maria,N.; Van Thiel,D. H.Digestive diseases and sciences 2000 ;45(9):1854-1860

Medical School
  • Amritsar Medical College/Punjab University
  • Amritsar Medical College Hospital, Internal Medicine: General
  • Sir HN Hospital, Internal Medicine: General
  • VA Medical Center, North Chicago/Chicago Medical School, Internal Medicine: General
  • Northwestern University McGaw Medical Center, Internal Medicine: Hematology & Medical Oncology
  • Hindi
  • Punjabi
  • Reading
  • Running
  • Chess